ArticleScientific reports2018
Probiotic Escherichia coli inhibits biofilm formation of pathogenic E. coli via extracellular activity of DegP.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 100 citations in OpenAlex.
- Acid-Mediated Antimicrobial Activity and Probiotic Potential of an SKS1-knockout Saccharomyces Cerevisiae Strain.Probiotics and antimicrobial proteins · 2026Article
- Molecular and biological characterization of a newly discovered Kayfunavirus bacteriophage targeting multidrug-resistant Escherichia coli from swine feces.Scientific reports · 2026Article
- Construction of an engineered Escherichia coli strain with enhanced intestinal colonization and anti-inflammatory efficacy in colitis.Cellular & molecular immunology · 2026Article
- Current and emerging approaches to manage chronic inflammatory gut disorders.Frontiers in cellular and infection microbiology · 2026Review
- Article
- Emerging Multimodal Strategies for Bacterial Biofilm Eradication: A Comprehensive Review.Microorganisms · 2025Review
- A microbiota-derived bile acid modulates biofilm formation by the probiotic strain Escherichia coli Nissle 1917.NPJ biofilms and microbiomes · 2025Article
- Synthetic Biology-Based Engineering Living Therapeutics for Antimicrobial Application.Exploration (Beijing, China) · 2025Article
- Not quite a cure yet: unlocking the unfulfilled promise of live biotherapeutics for disease treatment.Frontiers in pharmacology · 2025Article
- Combined Effect of DNase I and Proteinase K on Dual-Species Biofilm ofInternational journal of food science · 2025Article
- A comparativeFrontiers in microbiology · 2025Article
- The living medicine inside us:Gut microbes reports · 2025Article
- Harnessing the Power of Probiotics: Boosting Immunity and Safeguarding against Various Diseases and Infections.Recent advances in anti-infective drug discovery · 2025Review
- Investigation of the effect of anti-PIA/PNAG antibodies on biofilm formation inFrontiers in microbiology · 2025Article
- Secreted autotransporter toxin produced by probioticmicroPublication biology · 2025Article
- Nutrition ofEcoSal Plus · 2024Review
- Combating antibiotic resistance in a one health context: a plethora of frontiers.One health outlook · 2024Review
- A new standardization for the use of chicken embryo: selection of target from the phage display library and infection.Applied microbiology and biotechnology · 2024Article
- Klebsiella oxytoca inhibits Salmonella infection through multiple microbiota-context-dependent mechanisms.Nature microbiology · 2024Article
- Modulatory Effect of Competitive Exclusion on the Transmission of ESBL E. coli in Chickens.Probiotics and antimicrobial proteins · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many chronic infections involve bacterial biofilms, which are difficult to eliminate using conventional antibiotic treatments. Biofilm formation is a result of dynamic intra- or inter-species interactions. However, the nature of molecular interactions between bacteria in multi-species biofilms are not well understood compared to those in single-species biofilms. This study investigated the ability of probiotic Escherichia coli Nissle 1917 (EcN) to outcompete the biofilm formation of pathogens including enterohemorrhagic E. coli (EHEC), Pseudomonas aeruginosa, Staphylococcus aureus, and S. epidermidis. When dual-species biofilms were formed, EcN inhibited the EHEC biofilm population by 14-fold compared to EHEC single-species biofilms. This figure was 1,100-fold for S. aureus and 8,300-fold for S. epidermidis; however, EcN did not inhibit P. aeruginosa biofilms. In contrast, commensal E. coli did not exhibit any inhibitory effect toward other bacterial biofilms. We identified that EcN secretes DegP, a bifunctional (protease and chaperone) periplasmic protein, outside the cells and controls other biofilms. Although three E. coli strains tested in this study expressed degP, only the EcN strain secreted DegP outside the cells. The deletion of degP disabled the activity of EcN in inhibiting EHEC biofilms, and purified DegP directly repressed EHEC biofilm formation. Hence, probiotic E. coli outcompetes pathogenic biofilms via extracellular DegP activity during dual-species biofilm formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.